Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
Shionogi said on October 31 that its group operating profit in April-September dwindled 33.8% versus a year before in the face of a sizable increase in R&D spending, which was primarily driven by investments related to COVID-19. In the first…
To read the full story
Related Article
- Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
May 13, 2026
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
May 13, 2025
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
May 11, 2023
- Shionogi Hits Record High Earnings on Xocova Boon in FY2022
May 11, 2023
- Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
- Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
May 12, 2022
- Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
- Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement
April 26, 2022
- Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
February 1, 2022
- Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
November 2, 2021
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…